글로벌 항응고제 치료 시장 – 2031년까지의 산업 동향 및 예측

항응고제 치료 시장 분석 및 규모

항응고제 치료 시장은 최신 방법과 기술에 의해 주도되어 상당한 발전을 경험하고 있습니다. 이러한 성장은 새로운 경구 항응고제(NOAC) 및 정밀 의학 접근 방식과 같은 보다 효과적인 치료법에 대한 사용 및 수요 증가에 의해 촉진됩니다. 이러한 혁신은 보다 안전하고 맞춤화된 치료 옵션을 제공하여 환자 결과를 개선하는 것을 목표로 하며, 혈전성 질환 관리에서 변혁적인 단계를 표시합니다.                                

글로벌 항응고제 치료 시장 규모는 2023년에 299억 7천만 달러로 평가되었으며, 2031년까지 571억 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 8.39%입니다. 이는 시장 가치를 나타냅니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

시장 정의

항응고제 치료는 혈전증 위험이 있는 환자의 혈전 형성을 예방하기 위해 약물을 사용하는 것을 포함합니다. 와파린이나 헤파린과 같은 이러한 약물은 혈액의 응고 능력을 방해하여 혈관 내에서 위험한 응고 가능성을 줄입니다. 이 치료는 심부 정맥 혈전증, 폐색전증과 같은 상태를 관리하고 심방 세동이 있는 개인의 뇌졸중을 예방하는 데 중요합니다 .            

항응고제 치료 시장 역학

운전자

• 심혈관 질환의 유병률 증가

The rising global prevalence of cardiovascular diseases, including heart attacks and strokes, has fueled the demand for anticoagulation therapy. These conditions often require preventive measures against blood clotting to manage and reduce risks. For instance, atrial fibrillation, a common heart rhythm disorder, significantly increases the risk of stroke and necessitates ongoing anticoagulant treatment to prevent clot formation and potential stroke events, thereby driving growth in the anticoagulation therapy market.

• Growing Aging Population

The growing aging population is a pivotal driver for the anticoagulation therapy market. As people age, conditions such as atrial fibrillation and deep vein thrombosis become more prevalent. For instance, individuals over 65 are at higher risk of developing atrial fibrillation, necessitating anticoagulation therapy to prevent strokes. This demographic shift increases the demand for anticoagulants, contributing significantly to the expansion of the market for these therapies.

Opportunities

• Advancements in Anticoagulant Drugs

Advancements in anticoagulant drugs are driving the market by continually introducing more effective treatments. For instance, the development of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban offers patients alternatives to traditional therapies such as warfarin. These medications provide more predictable anticoagulation effects, require less frequent monitoring, and have lower risks of drug interactions, thereby improving patient outcomes and expanding the overall anticoagulation therapy market.

• Increasing Surgical Procedures

Increasing surgical procedures, particularly joint replacements and major orthopedic surgeries, drive the anticoagulation therapy market. These procedures often require prophylactic anticoagulation to prevent complications such as deep vein thrombosis (DVT) and pulmonary embolism (PE). For instance, after hip replacement surgery, patients are at high risk of DVT, necessitating the use of anticoagulants such as heparin or newer agents such as direct oral anticoagulants (DOACs). This demand fuels growth in the market for anticoagulation therapies. 

Restraints/Challenges

• Side Effects and Bleeding Risks

Anticoagulants pose significant risks of bleeding, especially in elderly patients or those with specific medical conditions, which hinders their market acceptance. The potential for severe bleeding events remains a critical concern, deterring broader adoption despite their therapeutic benefits in preventing thrombotic events. 

• High Cost of Therapy

The high cost of newer anticoagulants poses a significant barrier to market accessibility, particularly for patients lacking comprehensive insurance coverage or residing in lower-income regions. This financial constraint limits widespread adoption and availability, exacerbating disparities in access to essential anticoagulation therapies across global healthcare systems. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In July 2023, The Assure PT Care PT/INR Monitoring System, a collaboration between ARKRAY USA, Inc. and CoaguSense, Inc., will be available in long-term care institutions. This point-of-care test utilizes a proprietary micromechanical device for blood clotting time detection, comparable to WHO's tilt-tube method. Its wireless, portable design aims to enhance PT/INR testing productivity with instant results for timely patient care decisions
• In May 2023, Pfizer reported successful phase 3 results for marstacimab in treating hemophilia A and B, demonstrating efficacy without clotting issues. Annualized bleeding rates were significantly lower compared to current intravenous regimens, indicating clinical relevance. If approved, marstacimab would offer a flat dosage and be the first weekly subcutaneous treatment for hemophilia B
• In February 2022, Bayer's oral Factor Xia inhibitor Asundexian received fast-track designation from the FDA. In phase 2 trials, it promises safety advantages over existing anticoagulants. This potential therapy addresses a critical need for improved anticoagulation options
• In February 2022, Techdow USA Inc. launched its Heparin Sodium Injection, USP in the U.S. market. As a vertically integrated generic injectables company, this product aims to meet demand for high-quality injectable heparin sodium, contributing to healthcare accessibility and patient care in the United States

Anticoagulation Therapy Market Scope

The market is segmented on the basis of treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Arterial Thromboembolism (AT)
• Stroke
• Others

Therapeutic Class

• Novel Oral Anticoagulants (NOAC)
• Heparin
• Vitamin K Antagonists
• Others

 Drug Type

• Bivalirudin
• Dabigatran
• Edoxaban
• Betrixaban
• Rivaroxaban
• Apixaban
• Enoxaparin
• Dalteparin
• Others

 Route of Administration

• Oral
• Parenteral

 Therapeutic Area

• Cardiovascular
• Respiratory
• Oncology
• Nephrology
• CNS
• Others

 Procedure

• Pre-Surgical Procedures
• Post-Surgical Procedures
• Kidney Dialysis
• Heart Valve Replacement

Type

• Generics
• Branded

 End User

• Hospitals
• Clinics
• Homecare
• Ambulatory Surgical Centres
• Others

 Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Anticoagulation Therapy Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to expand at a significant growth rate due to the enduring administration, triple therapy anticoagulation, and increasing demand for anticoagulation drugs. The region's focus on long-term medical therapies drives the market for these treatments, reflecting sustained growth over the forecast period.

North America is expected to dominate the anticoagulation therapy market due to the proliferation of hospital-associated clinics and substantial healthcare expenditure in the region. These factors underscore its leading position in advancing anticoagulation treatments and patient care.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Anticoagulation Therapy Market Share Analysis

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 히크마 파마슈티컬스 PLC(요르단)
• 마일런 NV(네덜란드)
•  Teva Pharmaceutical Industries Ltd. (이스라엘)
• 노바티스 AG(스위스)
• 에자이 주식회사(일본)
• 파이저 주식회사(미국)
• 사노피(프랑스)
• F. 호프만-라 로슈 유한회사(스위스)
• Fresenius Kabi AG(독일)
• Aspen Holdings(남아프리카 공화국)
• 상하이 포선제약(그룹)유한공사(중국)
• Cipla Inc. (인도)
• 존슨앤존슨 서비스 주식회사(미국)
• Bayer AG(독일)
• 베링거인겔하임인터내셔널(독일)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 다이이치 산쿄 주식회사(일본)
• Eagle Pharmaceuticals, Inc. (미국)
• 엔도 인터내셔널 주식회사(아일랜드)
• 미쓰비시 타나베 파마 주식회사(일본)
• 포톨라 파마슈티컬스(미국)
• 타로제약산업(이스라엘)

SKU-28631